12:00 AM
 | 
Jul 02, 2007
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Keflex Pulsys: Phase III start

MBRK (formerly Advancis Pharmaceutical Corp.) will begin a double-blind, non-inferiority Phase III trial in >=600 patients to compare 1,200 mg Keflex PULSYS once daily vs. 250 mg of...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >